Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1

Conditions

Recurrence 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 308Cyclophosphamide 231Cytarabine 201Azacitidine 191fludarabine 181Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 82Rituximab 79Daunorubicin 77Dexamethasone 76Vincristine 69Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 58Tacrolimus 55Etoposide 53ibrutinib 52blinatumomab 51Granulocyte Colony-Stimulating Factor 51obinutuzumab 50Busulfan 50Prednisone 48Melphalan 48acalabrutinib 47Injections 47Stem Cell Transplantation 45Idarubicin 45Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
tapotoclax × Other hematologic neoplasm × 1 year × Clear all
NCT05209152 2025-07-14

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Amgen

Phase 1 Terminated
7 enrolled 16 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02675452 2025-07-09

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Amgen

Phase 1 Terminated
141 enrolled 46 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡